A photonic chip includes a substrate and several nanophotonic devices extending laterally away from an edge of the substrate. Each nanophotonic device is free-standing where it extends laterally past the edge of the substrate, with each neighboring pair of nanophotonic devices forming a gap therebetween. Atoms trapped in optical tweezers may be transported into the gap and close enough to a nanophotonic device that the atoms strongly couple to the nanophotonic device. Each nanophotonic device may include a waveguide, resonator, coupler, or a combination thereof. To excite modes of a nanophotonic device, a free-space optical beam may be coupled into a distal end of the nanophotonic device. A top face of each nanophotonic device may be reflective to create an optical lattice over the top face. An atom may then be trapped in the potential minimum of the optical lattice that is closest to the top face.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
2.
ENGINEERED RNA DEMETHYLASES FOR IMPROVED PLANT GROWTH
The present disclosure relates to engineered RNA m6A demethylases with disrupted low complexity regions (LCRs) for expression in plants, as well as recombinant DNA encoding the engineered RNA m6A demethylases, vectors encoding the recombinant DNA, plants including the engineered RNA m6A demethylases, and method of improving the growth of plants using the engineered RNA m6A demethylases, including increased root growth and elevated photosynthesis. The present disclosure further relates to methods of improving growth of a plant, including increased root growth and elevated photosynthesis, by modifying endogenous ALKBH5 homolog genes to include disrupted LCRs, and plants produced by those methods.
The present disclosure relates to engineered RNA m6A demethylases with disrupted low complexity regions (LCRs) for expression in plants, as well as recombinant DNA encoding the engineered RNA m6A demethylases, vectors encoding the recombinant DNA, plants including the engineered RNA m6A demethylases, and method of improving the growth of plants using the engineered RNA m6A demethylases, including increased root growth and elevated photosynthesis. The present disclosure further relates to methods of improving growth of a plant, including increased root growth and elevated photosynthesis, by modifying endogenous ALKBH5 homolog genes to include disrupted LCRs, and plants produced by those methods.
C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
4.
SYSTEM AND METHOD FOR LABORATORY DIAGNOSIS AND TREATMENT TARGETING IN IDIOPATHIC PSYCHOSIS VIA PSYCHOSIS BIOTYPES
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (USA)
YALE UNIVERSITY (USA)
THE UNIVERSITY OF CHICAGO (USA)
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (USA)
Inventeur(s)
Clementz, Brett A.
Mcdowell, Jennifer E.
Parker, David Alan
Keedy, Sarah
Keshavan, Matcheri S.
Tamminga, Carol A.
Pearlson, Godfrey D.
Gershon, Elliot S.
Ivleva, Elena Ivanovna
Abrégé
A method and system for diagnosing an idiopathic psychosis patient and improving treatment targeting for that patient. Cognitive performance is measured on the patient. Pro- and anti-saccade signals are measured on the patient. Motor inhibition is measured on the patient. EEG signals are measured on the patient. Principal components analysis is applied to the measured signals and scales to determine the most significant features. The patient is evaluating on at least 11 dimensions of neuro-cognitive performance. A trained numerical taxonomy approach is used to classify the patient as belonging to a B-SNP psychosis Biotype and the patient's condition is categorized based on the classified Biotype. The B-SNIP psychosis Biotype is used to implement targeted treatment for an individual patient. The diagnostic algorithm is continuously re-trained using new cases and new laboratory tests to improve precision of B-SNIP psychosis Biotypes diagnosis and the accuracy of selecting treatments for individual patients.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
N6-methyladenosine (m6A) is the most abundant internal modification on mammalian messenger RNA (mRNA). It is installed by a writer complex and can be reversed by erasers such as the fat mass and obesity-associated protein FTO. Despite extensive research, the primary physiological substrates of FTO in mammalian tissues and development remain elusive. Aspects disclosed show that FTO mediates m6A demethylation of long-interspersed element-1 LINE1 RNA in mouse embryonic stem cells (mESCs), regulating LINE1 RNA abundance and the local chromatin state, which in turn modulates transcription of LINE1-containing genes. FTO-mediated LINE1 RNA m6A demethylation also plays regulatory roles in shaping chromatin state and gene expression during mouse oocyte and embryonic development. FTO overexpression is also disclosed to modulate fertility.
In aspects, the invention provides a method of detecting a nucleotide modification in a sample comprising RNA, the method comprising: reacting RNA in the sample with periodate to form periodate-treated RNA in the sample, sequencing periodate-treated RNA in the sample, and detecting a modification signature in the sequence.
Methods for synthesizing ternary or higher-order group III-V nanocrystals from lower-order group III-V nanocrystals via ion-exchange in a molten inorganic salt containing a group III metal element are provided. In the methods, binary or higher-order group III-V nanocrystals are dispersed in an inorganic molten inorganic salt that contains a group III metal element having an oxidation state of less than III. In the molten inorganic salt, group III ions in the nanocrystals undergo ion-exchange with group III ions in the salt to increase the order of the group III-V nanocrystals.
B82B 3/00 - Fabrication ou traitement des nanostructures par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
C09K 11/08 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes
B82B 1/00 - Nanostructures formées par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
8.
Compositions and Methods for Treating Cancer and Viral Infections
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
A61K 38/00 - Préparations médicinales contenant des peptides
Aspects of the disclosure relate to a Effector system comprising at least one of each: i) a RNA hairpin binding domain; ii) a RNA targeting molecule comprising a RNA targeting region and at least one hairpin structure, wherein the hairpin structure of the RNA targeting molecule specifically binds to i; and iii) a Effector domain.
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
10.
METHODS AND DEVICES FOR ACQUIRING SUPER-RESOLUTION IMAGING WITH MODULATION
The present disclosure describes various methods, systems, and storage medium for acquiring super-resolution images with modulation. An apparatus includes a periodic pattern and a detector. The periodic pattern is configured to move to modify an original image field before the original image field propagates onto the detector of an imaging system, the original image field originating from a subject and comprising information of the subject, and the detector is configured to detect the modified original image field to acquire a plurality of detected images. The apparatus also includes a memory storing instructions and a processor in communication with the memory. When the processor executes the instructions, the processor is configured to cause the apparatus to reconstruct a super-resolution image based on the plurality of detected images, wherein an imaging resolution of the super-resolution image is better than an intrinsic resolution of the detector.
G06T 3/4076 - Changement d'échelle d’images complètes ou de parties d’image, p. ex. agrandissement ou rétrécissement basé sur la super-résolution, c.-à-d. où la résolution de l’image obtenue est plus élevée que la résolution du capteur utilisant les images originales basse résolution pour corriger itérativement les images haute résolution
11.
DIRECT SYNTHESIS OF COLLOIDAL NANOCRYSTALS IN A MOLTEN INORGANIC SALT SOLVENT
Methods of synthesizing nanocrystals are provided which comprise combining a metal molecular precursor comprising a transition metal element or a group III element, and a group V molecular precursor comprising a group V element, in a molten inorganic salt solvent comprising a molten inorganic salt and under conditions to form a metal-V compound in the form of nanocrystals. No organic solvent is required. Also provided are colloids comprising single-crystalline nanocrystals composed of a metal-V compound. This includes single-crystalline III-V nanocrystals that exhibit band edge photoluminescence upon illumination with light under room temperature.
B82B 3/00 - Fabrication ou traitement des nanostructures par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
C09K 11/08 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes
B82B 1/00 - Nanostructures formées par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
12.
OPTIC ELECTRONIC DEVICES AND METHODS FOR OPTICAL EPICARDIAL PACING
The present disclosure relates to optoelectronic devices and methods for optical epicardial pacing and endoscopic delivery devices and methods for translational photostimulation.
A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
A61B 1/06 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement
Systems and methods are provided to allow a user's lip to be used as a high temporal spatial resolution input and output surface. A stimulator is applied to the lip that includes a plurality of electrodes. These electrodes (e.g., a first subset) can be used to provide high-resolution electrohaptic stimulation to the lip, allowing the lip to be used to provide outputs of a user interface. These electrodes (e.g., a second subset) can also be used via capacitive or other sensing methods to detect the location of contact of the user's lip by the user's tongue and/or opposite lip, allowing the lip to be used to provide inputs to a user interface. Such a lip-based user interface provides hands-and eyes-free bidirectional information flow between a user and electronic systems, and does so in a manner that minimally impedes speech or eating.
A61F 4/00 - Procédés ou dispositifs permettant à des patients ou à des personnes handicapées de commander un appareil ou un dispositif ne faisant pas partie du corps
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
14.
System and method for non-obstructive electro-tactile stimulation of the palmar hand
Systems and methods are provided for providing electro-haptic stimulation to the palmar side of the hand without encumbering the hand, permitting a wearer to interact with objects normally while also receiving electro-haptic stimuli. This is accomplished by taking advantage of the higher threshold of stimulation needed to excite dorsal nerves of the hand relative to the palmar nerves of the hand, applying stimulating electrodes to the dorsal side of the hand and providing stimulation therethrough that is sufficient to elicit stimulation (and thus perceived haptic stimuli) of nerves in the palmar skin of the hand without stimulating nerves of the dorsal skin of the hand. Multiple electrodes can be provided to each finger, allowing for electro-haptic stimulation to be delivered to multiple different locations of each finger. The polarity of the stimulation can be controlled to deliver stimuli proximal or distal to a particular electrode.
This invention discloses methods and compositions for the treatment of demyelinating disorders. Specifically, the invention relates to the use guanabenz or guanabenz derivative for treating demyelinating disorders.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A method includes receiving a first plurality of aligned genomic sequences of a virus from a database. The aligned genomic sequences have a first common background. The method includes calculating a Qnet for each genomic sequence of the first plurality of aligned genomic sequences. The Qnet for each sequence is calculated by calculating a conditional inference tree for each index of the aligned genomic sequences using other indices in the aligned genomic sequences as predictive features, and calculating predictors for indices that were used as predictive features when calculating the conditional inference tree for each index.
Board of Regents, The University of Texas System (USA)
The University of Chicago (USA)
Inventeur(s)
Yankeelov, Thomas
Karczmar, Gregory
Wu, Chengyue
Hormuth, David
Oliver, Todd A.
Moser, Robert D.
Pineda, Federico
Easley, Ty
Barber, Rina F.
Kim, Byol
Sheth, Deepa
Oto, Aytekin
Abe, Hiroyuki
Medved, Milica
Fan, Xiaobing
Chatterjee, Aritrick
Wang, Shiyang
Abrégé
Disclosed are approaches to non-invasively characterize a tumor or other lesion in a region of interest (ROI) based on various analyses of magnetic resonance imaging (MRI) data. The MRI data may correspond to ultrafast dynamic contrast enhanced MRI (DCE-MRI) and high spatial resolution DCE-MRI scans, and diffusion-weighted MRI (DW-MRI) scans of the ROI. Vasculature metrics may be determined, and tumor-associated blood flow velocity and/or tumor interstitial pressure may be obtained using the vasculature metrics as inputs to a computational fluid dynamics model. A combination of morphological vascular metrics and functional vascular metrics may be used to characterize the tumor. Malignancy, aggressiveness, treatment response, and other features of tumors or other lesions, in the breast or other regions of a patient, may be characterized through disclosed analyses of MRI data.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
G06T 3/40 - Changement d'échelle d’images complètes ou de parties d’image, p. ex. agrandissement ou rétrécissement
A61K 9/1273 - PolymersomesLiposomes comportant des substances polymérisables ou polymérisées formant des bicouches
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
An embodiment may involve determining a network traffic rate for a link; determining an amount of available memory for classification in a computing system operationally coupled to the link; selecting a classifier from a plurality of classifiers, wherein the classifiers are respectively associated with a time usage and a memory usage, wherein the classifiers were trained to predict network traffic types based on network traffic flows, and wherein the selection is based on: the network traffic rate, an amount of available memory, and the time usage and the memory usage of the classifier; and deploying the classifier to receive incoming network traffic flows by way of the link.
H04L 47/2441 - Trafic caractérisé par des attributs spécifiques, p. ex. la priorité ou QoS en s'appuyant sur la classification des flux, p. ex. en utilisant des services intégrés [IntServ]
H04L 41/16 - Dispositions pour la maintenance, l’administration ou la gestion des réseaux de commutation de données, p. ex. des réseaux de commutation de paquets en utilisant l'apprentissage automatique ou l'intelligence artificielle
20.
Methods and Systems for Modulating Cellular Activation
This disclosure relates to methods for modulating activity of a cell capable of being activated by light and treating diseases with such methods. The disclosure also provides systems suitable for use in such methods, particularly systems having silicon nanostructures.
A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A method for classifying a mass in a medical image includes segmenting the medical image into a mass image and a background image, separating the mass image into a first mass component and a second mass component, extracting a set of radiomic-feature values from the first mass component and the second mass component, and processing the set of radiomic-feature values to classify the mass as malignant or benign. The mass image may be separated by clustering the pixels forming the mass image (e.g., using fuzzy c-means clustering). The method also includes outputting an indication that the mass is malignant or benign. The indication may be used to screen for, diagnose, treat, or monitor cancer in a human patient from which the medical image was obtained. The method may be implemented for use with ultrasound images, x-ray images, CT-scan images, PET-scan images, and MRI images.
G06F 18/40 - Dispositions logicielles spécialement adaptées à la reconnaissance des formes, p. ex. interfaces utilisateur ou boîtes à outils à cet effet
The disclosure is directed to systems, devices, and methods for generating, stabilizing, and controlling mesoscopic spin order of electrons. The device includes a two-dimensional (2D) semiconductor monolayer configured to accommodate a 2D electron gas; and a first receptacle configured to receive a first optical beam. The first optical beam is configured to interact with the 2D electron gas at a first in-plane spatial position to generate a mesoscopic magnetic/spin state of electrons in the 2D semiconductor monolayer in absence of an external magnetic field. The method includes providing a structure comprising a 2D semiconductor monolayer configured to provide a 2D electron gas; and applying a first optical beam to interact with the 2D electron gas at a first in-plane spatial position to generate a mesoscopic magnetic/spin state of electrons in the 2D semiconductor monolayer in absence of an external magnetic field.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Zhou, Hengyun
Ataides, Juan Pablo, Bonilla
Bluvstein, Dolev
Wurtz, Jonathan
Lukin, Mikhail, D.
Xu, Qian
Jiang, Liang
Pattison, Christopher, A.
Raveendran, Nithin
Vasic, Bane
Abrégé
Quantum error correction in reconfigurable atom arrays is described. A plurality of data qubits is provided, each of the plurality of data qubits disposed in a corresponding trap. A plurality of ancilla qubits is provided, each of the plurality of ancilla qubits disposed in a corresponding trap. The plurality of data qubits and the plurality of ancilla qubits are arranged in a plurality of rows and a plurality of columns, thereby forming a lattice. A plurality of permutations of the plurality of rows and the plurality of columns is performed, each of the plurality of permutations placing each of the plurality of data qubits within an interaction radius of one of the plurality of ancilla qubits, thereby forming a plurality of proximate pairs. Subsequent to each of the plurality of permutations, a global control pulse is applied to the lattice, thereby applying a gate to each of the plurality of proximate pairs, and thereby encoding a parity check matrix between the plurality of ancilla qubits and the plurality of data qubits.
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
CALIFORNIA INSTITUTE OF TECHNOLOGY (USA)
THE UNIVERSITY OF CHICAGO (USA)
Inventeur(s)
Zhou, Hengyun
Ataides, Juan, Pablo, Bonilla
Bluvstein, Dolev
Wurtz, Jonathan
Lukin, Mikhail, D.
Xu, Qian
Jiang, Liang
Pattison, Christopher, A.
Raveendran, Nithin
Vasic, Bane
Abrégé
Constant-overhead fault-tolerant quantum computation is provided. A first plurality of physical qubits is configured to encode a first plurality of logical qubits using a quantum low-density parity-check (qLDPC) code. A second plurality of physical qubits is configured to encode a second plurality of logical qubits using an error-correcting code; and a plurality of ancilla qubits. The quantum computing system is configured to teleport at least one of the first plurality of logical qubits into a corresponding at least one of the second plurality of logical qubits via the plurality of ancilla qubits. The quantum computing system is configured to perform at least one logical operation on the at least one of the second plurality of logical qubits. The quantum computing system is configured to teleport the at least one of the second plurality of logical qubits into the at least one of the first plurality of qubits via the plurality of ancilla qubits.
The current disclosure relates to methods, compositions and kits for detecting modified adenosine in a target RNA molecule. Aspects relate to a method for detecting modified adenosine in a target ribonucleic acid (RNA) comprising contacting the target RNA with an adenosine deaminase enzyme (adenosine deaminase, RNA-specific) to generate a target RNA with deaminated adenosines and sequencing the target RNA with deaminated adenosines; wherein the modified adenosine is detected when the nucleotide sequence includes adenosine within a m6A motif.
Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61J 1/00 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/567 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en position 17 alpha, p. ex. mestranol, noréthandrolone
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
TT states to generate one or more distilled magic states; b) measure out a plurality of syndromes from the distillation; c) calculate one or more error rates from the plurality of syndromes; d) estimate infidelity for the distillery based upon the one or more error rates; and e) determine if the infidelity exceeds a threshold, recalibrate the distillery.
G06N 10/70 - Correction, détection ou prévention d’erreur quantique, p. ex. codes de surface ou distillation d’état magique
G06F 11/07 - Réaction à l'apparition d'un défaut, p. ex. tolérance de certains défauts
G06N 10/00 - Informatique quantique, c.-à-d. traitement de l’information fondé sur des phénomènes de mécanique quantique
G01R 31/3177 - Tests de fonctionnement logique, p. ex. au moyen d'analyseurs logiques
G06N 10/20 - Modèles d’informatique quantique, p. ex. circuits quantiques ou ordinateurs quantiques universels
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
G06F 30/33 - Vérification de la conception, p. ex. simulation fonctionnelle ou vérification du modèle
H03M 13/00 - Codage, décodage ou conversion de code pour détecter ou corriger des erreursHypothèses de base sur la théorie du codageLimites de codageMéthodes d'évaluation de la probabilité d'erreurModèles de canauxSimulation ou test des codes
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Providing information in the field of economics (terms
considered too vague by the International Bureau - Rule 13
(2) (b) of the Regulations). Educational services, namely, conducting classes in the
field of economics at the university undergraduate and
graduate level and providing publications, namely,
educational materials in connection therewith; educational
services, namely, conducting classes in the field of
economics at the university undergraduate and graduate level
and providing course materials in connection therewith;
providing educational course materials for high school
classes in the field of economics; providing training in the
field of economics and distribution of educational materials
in connection therewith for high school teachers.
Provided are battery binder compositions. In embodiments, a battery binder composition comprises cellulose in the form of nanocellulose or microcellulose, the cellulose comprising electrode binding groups and solvent dispersing groups; and a non-aqueous solvent system. Battery electrodes and batteries comprising the battery binder compositions are also provided.
Aspects of the disclosure relate to nucleic acid compositions involving small nucleolar RNAs (snoRNAs), including for increasing secretion of a protein of interest. Aspects also relate to methods of using the nucleic acid compositions.
Described herein are novel γ- and δ-propargyl carboxylic acids and esters. The novel compositions are antagonists of CSE and may be used to modulate of the activity of the carotid body, therefore providing therapeutic benefits for sleep-related breathing disorders and related conditions.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A61K 31/221 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine avec des composés ayant un groupe amino, p. ex. acétylcholine, acétylcarnitine
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
C07C 229/30 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et non saturé
C07D 277/30 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 333/24 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
The University of North Carolina at Chapel Hill (USA)
Inventeur(s)
Pandarinath, Chethan
Zhu, Feng
Kaufman, Matthew Tyler
Sedler, Andrew Robert
Giovannucci, Andrea
Abrégé
The present disclosure provides novel training systems and methods for recurrent neural network models. One such method comprises obtaining a first sequence of sparse input data as training data; augmenting the first sequence of sparse input data by zero-filling missing input points; training the recurrent neural network model using the augmented sequence of sparse input data to obtain a trained recurrent neural network model, and applying new data as an input to the trained recurrent neural network model, wherein the new data comprises a second sequence of sparse input data to obtain a corresponding output data sequence.
G06V 10/774 - Génération d'ensembles de motifs de formationTraitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source méthodes de Bootstrap, p. ex. "bagging” ou “boosting”
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
33.
NANOPARTICLE-CONTAINING MEDIA EXHIBITING ENHANCED OPTICAL TRANSPARENCY, RELATED NANOPARTICLES, AND ASSOCIATED SYSTEMS AND METHODS
The present disclosure is generally directed to nanoparticle-containing media exhibiting enhanced optical transparency, related nanoparticles, and associated systems and methods. In certain embodiments, the refractive index (RI) of a nanoparticle comprising thermochromic material (such as VO2) can be made closer to the refractive index of a surrounding medium by tethering a material (such as a gradient copolymer) to the core region of the nanoparticle to modify the refractive index of the nanoparticle. Modifying the refractive index of the nanoparticle to be closer to the refractive index of the medium that contains the nanoparticle can render the nanoparticle-containing medium (also referred, to herein as a composite) more transparent to various wavelengths of electromagnetic radiation while imparting thermochromic properties to the nanoparticle-containing medium.
C09C 3/00 - Traitement, en général, de substances inorganiques, autres que des charges fibreuses, pour améliorer leurs propriétés de pigmentation ou de charge
C09C 3/06 - Traitement par des composés inorganiques
C09C 3/10 - Traitement par des composés organiques macromoléculaires
C09D 5/29 - Compositions de revêtement, p. ex. peintures, vernis ou vernis-laques, caractérisées par leur nature physique ou par les effets produitsApprêts en pâte pour effets multicolores
C09D 7/62 - Adjuvants non macromoléculaires inorganiques modifiés par traitement avec d’autres composés
C09K 9/00 - Substances devenant sombres, c.-à-d. substances pour lesquelles la gamme de longueurs d'onde absorbées est modifiée par excitation avec une énergie sous une forme quelconque
34.
COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SpA) VARIANTS
The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present disclosure relates to a biomaterial matrix having a live bacteria impregnated hydrogel, using the biomaterial matrix to treat epidermal inflammation of an animal, and wearable electronic devices having the biomaterial matrix installed thereon.
Provided herein are compositions and methods for stimulating T-cell-based anti-tumor immunity by administration of trans-vaccenic acid (TVA), an active derivative thereof, or an inhibitor of GPR43 expression or activity. In particular embodiments, TVA, a TVA derivative, or an inhibitor of GPR43 expression or activity is administered to boost an endogenous T-cell response and/or is co-administered with a T-cell-based therapy, such as immune checkpoint blockade therapies, CAR-T therapies, monoclonal antibody therapies, bispecific T-cell engagers therapies, etc.
A61K 31/201 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant une ou deux doubles liaisons, p. ex. acides oléique ou linoléique
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
The current disclosure provides for methods for diagnosing, prognosing, and treating cerebral cavernous malformations (CCMs). Also provided are methods for determining the efficacy of therapeutic treatments for CCM, such as those that may be in a clinical trial setting or administered by a health care professional. Accordingly, aspects of the disclosure relate to method for treating cerebral cavernous malformations (CCMs) in a subject, the method comprising administering a therapy to a subject determined to have differential expression of one or more biomarkers selected from the biomarkers listed in Tables S1-S8 and S13 in a biological sample from the subject. Further aspects relate to A method for treating cerebral cavernous malformations (CCMs) in a subject, the method comprising administering a therapy to a subject determined to have differential expression of one or more biomarkers selected from let-7e-5p, miR-93-5p, miR-20b-5p, miR-128-3p, miR-9-5p, IL-10, Tsp-2, IL-2, and TNER1.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
38.
OPTICALLY ADDRESSABLE MOLECULAR-SPIN QUBIT DILUTED IN A HOST MATRIX
A molecular-spin qubit includes a molecular color center having a ground state and an excited state. The ground state has non-zero spin with at least first and second sublevels. The molecular-spin qubit also includes a host matrix that is non-isostructural with the molecular color center. The molecular color center is diluted in the host matrix. An optical transition between the ground and excited states lies in the optical region of the electromagnetic spectrum. A spin transition between the first and second sublevels lies in the microwave or millimeter-wave regions of the electromagnetic spectrum. Each of the first and second sublevels is first-order insensitive to magnetic fields near zero magnetic. The molecular color center and host matrix may each be formed from strong-field ligands bound to a metal-atom center. One example of the molecular-spin qubit is Cr(IV)(o-toyl)4 diluted in a host matrix of Sn(IV)(4-fluoro-2-methylphenyl)4.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
Stretchable light-emitting polymers are provided. Stretchable organic light-emitting diodes including the stretchable light-emitting polymers are further provided.
H10K 50/11 - OLED ou diodes électroluminescentes polymères [PLED] caractérisées par les couches électroluminescentes [EL]
C08F 26/06 - Homopolymères ou copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par une liaison simple ou double à l'azote ou par un hétérocycle contenant de l'azote par un hétérocycle contenant de l'azote
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
An optical cavity includes a plurality of mirrors that reflect light along a closed path. First and second mirrors of the plurality of mirrors define an optical axis therebetween. The optical cavity includes first and second lenses located between the first and second mirrors along the optical axis. A mode of the optical cavity has a waist located between the first and second intracavity lenses. Small values of the waist (e.g., <10 microns) produce large cooperativities that relax requirements for the cavity finesse (i.e., reflectivity of the mirrors). The mirrors may be retroreflecting to create a Fabry-Perot cavity. Alternatively, the first and second mirrors may define one segment of a ring cavity. The optical cavity may be used to trap, read, entangle, and drive nonlinear emitters (e.g., atoms, color centers, quantum dots) located near the waist.
Provided herein are pharmaceutical compositions and dietary supplements comprising vanadyl sulfate (VS) and method of use thereof for the induction of cell death in senescent cells. In particular. VS compositions find use in clearance of age-related and/or therapy-induced senescent cells and reduction/elimination of senescence associated secretory phenotype (SASP)-induced inflammatory environments in subjects. and therefore in the treatment/prevention of age-related conditions and/or cancer.
Described herein are polymersomes (PSs) as a delivery platform that display enhanced macromolecular encapsulation efficiency with facile, streamlined processing. The formulations herein demonstrate rapid assembly of near-monodisperse PSs without organic solvents to circumvent purification issues. This is achieved through two design principles: 1) temperature responsive PS assembly and 2) affinity-driven payload encapsulation. The BCPs are solubilized in aqueous buffer when refrigerated (4 °C) but self-assemble at room temperature (20 °C) into homogeneous PSs. This is achieved by incorporating polymers segments with a lower critical solution temperature (LCST) below room temperature but above the freezing point of water. BCPs are dissolved alongside a hydrophilic payload, and their uniform self-assembly bypasses solvent and size-exclusion purifications.
C08G 81/00 - Composés macromoléculaires obtenus par l'interréaction de polymères en l'absence de monomères, p. ex. polymères séquencés
C08L 33/06 - Homopolymères ou copolymères des esters d'esters ne contenant que du carbone, de l'hydrogène et de l'oxygène, l'oxygène, faisant uniquement partie du radical carboxyle
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
Systems and methods for delivering a drug to a patient's kidney. The present systems comprise a urethral catheter and a ureteral catheter sized to fit through the urethral catheter. The urethral catheter includes a balloon configured to be inflated in the patient's bladder to retain the urethral catheter in the patient's urethra. The ureteral catheter includes a balloon configured to be inflated in the patient's ureter and/or kidney while a distal end of the ureteral catheter is disposed in the patient's kidney. The ureteral catheter balloon can help retain liquid in the kidney to enable expanded contact areas with kidney tissues and extended dwell times (e.g., periods of exposure) of the drug in the kidney. The balloons also help retain the catheters in the patient's urinary tract, such that the catheter system can be used to deliver a drug to the patient's intermittently or periodically over a period of days or weeks.
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
44.
DIAMOND MATERIALS WITH REDUCED HYDROGEN-PASSIVATED DEFECTS AND ASSOCIATED FABRICATION METHODS
The present disclosure includes an arm support for supporting a patient's arm during a procedure, such as a cardiac catheterization procedure. Some arm supports include a unitary body defining: a lower portion, an upper portion, a first end, a second end, a proximal side, and a distal side of the arm support, where the lower portion of the unitary body defines a mount configured to be coupled to a patient support, and where the upper portion of the unitary body defines a support surface extending between the first and second ends, where the support surface is shaped to support a patient's arm.
Disclosed are compositions and methods useful for cancer treatment. The composition and methods include overexpressing BAMBI in a population of immune cells, such as myeloid-derived suppressor cells, in order to improve the immune cells immunogenic and/or anti-tumor effects. Also disclosed are compositions and methods for determining responsiveness to a radiotherapy and/or immunotherapy.
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/078 - Cellules du sang ou du système immunitaire
47.
COMPOSITIONS, KITS, AND METHODS FOR ASSESSING MICROBIOME HEALTH
The present disclosure provides compositions and methods related to microbiome health. In particular, the present disclosure provides novel compositions, kits, and methods for treating and/or monitoring the microbiome health of a subject using metabolic biomarkers.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
UNIVERSITY OF CHICAGO (USA)
LEIDOS BIOMEDICAL RESEARCH, INC. (USA)
SCHRODINGER, INC. (USA)
CURIA GLOBAL, INC. (USA)
Inventeur(s)
Stott, Gordon
Green, Neal
Eckert, Mark
Allega, Maria Francesca
White, Andrew
Wolf, Mark Allan
Abrégé
NN-methyltransferase (NNMT) which have a triazolone-piperidine scaffold. The NNMT inhibitors are useful for treating tumors and cancers, metabolic disorders and liver disorders.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
49.
SYSTEMS AND METHODS FOR OPTIMIZED PULSES FOR CONTINUOUS QUANTUM GATE FAMILIES THROUGH PARAMETER SPACE INTERPOLATION
A quantum computing system for optimizing instructions of a quantum circuit is configured to: select reference points in a parameter space of a family of gates that are executable by the quantum processor; identify edges in the parameter space connecting two reference points; compute a pulse vector for each reference point of the plurality of reference points; optimize the pulse vector for each reference point of the plurality of reference points based on the first pulse vector of each neighboring reference point connected to that reference point by an edge; receive a target operation from the quantum circuit for optimization; compute a second pulse vector for the target operation based on interpolating between a subset of reference points of the plurality of reference points; and executed the target operation on a quantum processor using the pulse vector for the target operation.
G06N 10/60 - Algorithmes quantiques, p. ex. fondés sur l'optimisation quantique ou les transformées quantiques de Fourier ou de Hadamard
G06N 10/80 - Programmation quantique, p. ex. interfaces, langages ou boîtes à outils de développement logiciel pour la création ou la manipulation de programmes capables de fonctionner sur des ordinateurs quantiquesPlate-formes pour la simulation ou l’accès aux ordinateurs quantiques, p. ex. informatique quantique en nuage
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
In some aspects, provided herein are methods for treating a liver disease or associated condition in a subject, and related compositions. In some embodiments, the composition comprises lactulose and a commensal organism, such as a commensal bacterial species. In some embodiments, the patient has been determined to have a microbiome profile and metabolic profile in a fecal sample from the patient, which may be indicative that the patient will benefit from the treatment.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
51.
LOW-DOSE TOCILIZUMAB FOR THE TREATMENT OR PREVENTION OF SICKLE CELL CRISIS
Provided herein are methods for the treatment or prevention of sickle cell crisis and symptoms associated therewith by the administration of low doses of tocilizumab to a subject. In particular embodiments, provided herein are pharmaceutical compositions comprising doses of 200 mg or less of tocilizumab and methods for the treatment or prevention of sickle cell crisis and symptoms or other conditions arising as a result thereof.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
52.
FUNCTIONALIZED NANOPARTICLES FOR THE CONTAINMENT AND CLEARANCE OF PATHOGENS
Functionalized nanoparticles for inhibiting or preventing pathogen infections (e.g., viral or bacterial infections, such as coronavirus infections) are described. The nanoparticles comprise a biodegradable polymer core and a lipid coating layer that is functionalized with a pathogen-binding receptor (e.g., an angiotensin-converting enzyme 2 (ACE2) receptor protein) and/or a pathogen-binding antibody or an antigen-binding fragment thereof (e.g., a virus-binding antibody or an antigen-binding fragment thereof). The nanoparticles are further functionalized by a phagocyte-specific ligand, e.g., a phosphatidylserine-containing lipid included in the lipid coating layer, to promote clearance of nanoparticle-bound pathogen. Methods of using the nanoparticles to treat or prevent pathogen infections (e.g., coronavirus infections) are also described.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
Aspects of the present disclosure are directed to growth hormone receptor (GHR)-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such GHR-targeting polypeptides and cells comprising such nucleic acids. Described are methods for treatment of acromegaly using GHR-targeting polypeptides.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
Example embodiments allow for networks of hybrid controllers that can be computed efficiently and that can adapt to changes in the system(s) under control. Such a network includes at least one hybrid controller that includes a dynamic sub-controller and a learned system sub-controller. Information about the ongoing performance of the system under control is provided to both the hybrid controller and to an over-controller, which provides one or more control inputs to the hybrid controller in order to modify the ongoing operation of the hybrid controller. These inputs can include the set-point of the hybrid controller, one or more parameters of the dynamic controller, and an update rate or other parameter of the learned system controller. The over-controller can control multiple hybrid controllers (e.g., controlling respective sub-systems of an overall system) and can, itself, be a hybrid controller.
G05B 13/02 - Systèmes de commande adaptatifs, c.-à-d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques
G05B 13/04 - Systèmes de commande adaptatifs, c.-à-d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques impliquant l'usage de modèles ou de simulateurs
Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Girdle Muscular Dystrophy.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
56.
WAFER-SCALE WAVEGUIDES FOR INTEGRATED TWO-DIMENSIONAL PHOTONICS
Systems and methods for generating and manipulating a guided electromagnetic wave in a waveguide are provided. The optical system includes a waveguide, such as a two-dimensional waveguide, and an optical element disposed adjacent the surface of the waveguide. To generate the guided electromagnetic wave, a converging laser beam is generated and coupled to the waveguide by steering the converging laser beam towards an edge of the waveguide and with a beam center trajectory approximately parallel to a surface of the waveguide.
Systems and methods for performing laser lithotripsy include introducing a lithotripsy medium containing nanoparticles into a body cavity comprising target obstructions and applying laser energy through the lithotripsy medium to disrupt the target obstructions. The nanoparticles may have diameters configured to enhance absorption efficiency of the laser energy. The nanoparticles may include organic polymers such as PEDOT: PSS or inorganic compounds such as indium tin oxide. Systems may include a laser source, a fluid delivery component configured to deliver the nanoparticle-containing lithotripsy medium, and an optical fiber for delivering laser energy. Methods of manufacturing lithotripsy media include selecting target wavelengths, synthesizing nanoparticles with corresponding absorption characteristics, and dispersing the nanoparticles at selected concentrations.
A61B 18/24 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes en utilisant des lasers le faisceau étant dirigé le long, ou à l'intérieur d'un conduit flexible, p. ex. d'une fibre optiquePièces à main à cet effet avec un cathéter
A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
58.
ENCAPSULATED FLYWHEEL ACTUATION MODULES AND METHODS AND SYSTEMS FOR USING, DESIGNING, AND PROTOTYPING WITH FLYWHEEL ACTUATION MODULES
An actuator module includes a motor, a flywheel coupled to the motor and configured to be rotated by the motor, a power source, a controller coupled to the power source and the motor, and a housing enclosing the motor, the flywheel, the power source, and the controller. The controller is programmed to operate the motor using the power source in response to instructions received from a remote device.
A63H 30/04 - Agencements électriques par transmission sans fil
A63H 33/08 - Blocs, bandes ou autres éléments pour les jeux de construction assemblés sans emploi de pièces additionnelles pourvus de trous, rainures ou saillies complémentaires, p. ex. queue d'aronde
Methods of separating rare earth elements, such as lanthanides, from an aqueous solution that includes two or more different types of rare earth elements are provided. The methods use confined solid ionic channels in layered, mixed metal oxides to separate different rare earth ions based on hydration shell size, dehydration energy, binding affinity, and/or hydration phase transformations.
Because of its myeloid-specific expression, it was hypothesized that CD200R could provide both an inhibitory signal and a target for antigen delivery to antigen presenting cells if antigens are fused recombinantly to a soluble CD200. The examples demonstrate that immunological tolerance can be established using antigen-fused CD200 molecules, including CD200Fc- fused antigen. This tolerance was demonstrated by abrogating responses to immune challenge and induction of production of tolerogenic cytokines, including IL- 10. Accordingly, the polypeptides, compositions, and methods are useful for tolerization of any antigen, such as any antigen related to autoimmune conditions, allergy conditions, anti-drug immunity conditions, among others. Described here is a polypeptide comprising a CD200 polypeptide operatively linked to an antigen. Also provided is a nucleic acid encoding a polypeptide, an expression vector comprising a nucleic acid of the disclosure, host cells comprising a polypeptide of the disclosure. Also described are methods utilizing the polypeptides and compositions.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
Systems and methods are disclosed for predicting the rise of different strains of viruses. A method comprises reading a genetic sequence of a first strain of a virus; identifying a plurality of residue indices in the genetic sequence; for each of the plurality of indices, assigning a predictor, the predictor configured to predict a residue for its assigned index based upon a residue of at least one other index, the predictors thereby forming a network; and determining, based on the network of predictors, a probability of transition of the first strain to a second strain.
G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p. ex. de la grippe
G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
62.
COMPOSITIONS AND METHODS RELATED TO MODIFICATION AND DETECTION OF PSEUDOURIDINE AND 5-HYDROXYMETHYLCYTOSINE
Aspects of the present disclosure are directed to methods and compositions for modification, detection, and quantification of pseudouridine and 5-hydroxymethylcytosine. Disclosed are methods for modification of pseudouridine and/or 5-hydroxymethylcytosine comprising bisulfite treatment under particular conditions. Further disclosed are compositions and kits comprising a bisulfite solution and instructions for use.
The Board of Trustees of the University of Illinois (USA)
Inventeur(s)
Weber, Christopher R.
Shen, Le
Khalili-Araghi, Fatemeh
Abrégé
Provided is a method of treating a disorder mediated by claudin-2 and/or claudin-15, particularly an intestinal disorder, such as colitis or enteritis. The method comprises administering to the subject an effective amount of a compound of formula (I), formula (II), or otherwise as described herein or a pharmaceutically acceptable salt thereof. In another aspect, also provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof.
C07D 239/06 - Composés hétérocycliques contenant des cycles diazine-1, 3 ou diazine-1, 3 hydrogéné non condensés avec d'autres cycles comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique
A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 31/536 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes carbocycliques
C07D 233/24 - Radicaux substitués par des atomes d'azote ne faisant pas partie d'un radical nitro
64.
MATERIALS AND METHODS FOR LARGE-SCALE SPATIAL TRANSCRIPTOMICS
The present disclosure relates to materials and methods for large-scale spatial transcriptomics. In particular, the disclosure provides methods for producing systems for spatial transcriptomics, along with materials and methods for determining the spatial location of a desired nucleic acid, such as RNA, within a tissue sample.
The current disclosure relates to nucleic acid therapeutics that target mRNA molecules and recruit translation machinery to increase the translation from the mRNA, thus increasing the protein product in a subject or cell. Accordingly, aspects of the disclosure relate to a chimeric nucleic acid comprising a targeting region and a translational activating region, wherein the translational activating region comprises at least one ribosome and/or translation factor binding site and wherein the targeting region comprises a region that is complementary to a target mRNA. Further described are circular nucleic acids comprising a targeting region and a translational activating region, wherein the translational activating region comprises at least one ribosome and/or translation factor binding site and wherein the targeting region comprises a region that is complementary to a target mRNA.
A structured illumination microscopy system includes a plurality of lights sources. Each light source emits an excitation beam. The excitation beams vary in wavelength. The system also includes a plurality of dichroic mirrors positioned to collimate the excitation beams emitted from the plurality of light sources into a multicolor beam. A blazed grating is positioned to receive the multicolor beam and to disperse the multicolor beam into a plurality of monochrome beams. The blazed grating directs the monochrome beams toward a digital micromirror device, which is positioned to receive the plurality of monochrome beams from the blazed grating and to direct the plurality of monochrome beams toward a sample. An image sensor is positioned between the digital micromirror device and the sample. The image sensor generates an image of the sample based at least in part on an interaction of the plurality of monochrome beams and the sample.
A coherence model predicts the coherence time of one spin qubit based on decoherence caused by a surrounding spin bath. This coherence model, which is constructed by performing cluster correlation expansion calculations of spin-bath-induced decoherence, includes a library of coherence time distributions over a parameter-space range. Using this library, maximum likelihood estimation is then performed on a set of experimental data, enabling the density of the spin bath and the dimensionality of the spin qubits to be determined, given certain geometrical constraints. Rather than relying on assumptions that average over interactions between bath spins and central qubit spins, the present embodiments simulate the dynamics of the entire interacting spin bath, producing a quantum mechanical characterization technique for quantum applications that can be incorporated into a feedforward synthesis loop.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
G01N 24/12 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance double
G06N 10/20 - Modèles d’informatique quantique, p. ex. circuits quantiques ou ordinateurs quantiques universels
G06F 30/3308 - Vérification de la conception, p. ex. simulation fonctionnelle ou vérification du modèle par simulation
G06N 10/80 - Programmation quantique, p. ex. interfaces, langages ou boîtes à outils de développement logiciel pour la création ou la manipulation de programmes capables de fonctionner sur des ordinateurs quantiquesPlate-formes pour la simulation ou l’accès aux ordinateurs quantiques, p. ex. informatique quantique en nuage
G06N 10/00 - Informatique quantique, c.-à-d. traitement de l’information fondé sur des phénomènes de mécanique quantique
Technologies for resource-efficient quantum error correction are disclosed. A quantum computer may include physical gate qubits, capable of general quantum gate operations such as single-qubit operations and nearest-neighbor two-qubit operations. Each physical qubit gate may be controllably coupled to a quantum memory. The quantum memory may have a lower per-gate error rate than the physical qubit gates as well as a lower per-qubit cost. Because errors accrue at a lower rate in the quantum memory, the physical gate qubits may be able to perform error correction for a large number of logical qubits in the quantum memory, even if the physical gate qubits have an error rate relatively close to an error threshold.
G06N 10/70 - Correction, détection ou prévention d’erreur quantique, p. ex. codes de surface ou distillation d’état magique
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
70.
BCL-2 INHIBITION TO AMPLIFY CHIMERIC ANTIGEN RECEPTOR THERAPY
Provided herein are methods of preparing an immunotherapeutic with enhanced efficacy by treating lymphocytes with a B-cell lymphoma 2 (BCL-2) inhibitor, immunotherapeutic compositions produced by the methods herein, and methods of treating cancer therewith.
Aspects of the present disclosure are directed to synthetic DNA binding peptides, as well as methods of generating such peptides and methods for use of such peptides in, for example, DNA binding, modifying gene expression, and treatment of various conditions such as cancer, fibrosis, and diabetes. Certain aspects provide synthetic DNA binding dimers comprising two modified bZIP peptides, each comprising a modified basic domain and a modified leucine zipper domain and linked via an interpeptide linker (e.g., a side-by-side interpeptide linker). Also disclosed are universal methods for generating high affinity synthetic DNA binding dimers from any bZIP protein.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
Aspects of the present disclosure are directed to borealin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such borealin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using borealin-targeting polypeptides.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
73.
DESIGNING BACTERIAL COMMUNITIES USING MACHINE LEARNING
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for training a machine learning model that is configured to process a model input that defines a bacterial community to generate a predicted score that predicts a performance of the bacterial community in performing a bacterial task. According to one aspect, a method comprises: generating data identifying a set of bacterial communities; obtaining, for each bacterial community, a target score for the bacterial community; generating a set of training examples, wherein each training example corresponds to a respective bacterial community and comprises: (i) a training input that identifies the bacterial strains included in the bacterial community, and (ii) the target score for the bacterial community; training the machine learning model on the set of training examples; and identifying one or more candidate bacterial communities for performing the bacterial task using the trained machine learning model.
The present disclosure provides macrocyclic and macrobicyclic peptides with secondary structures that are stabilized over the corresponding non-cyclic peptides. The macrocyclic and macrobicyclic peptides are formed from peptides with adduct-forming, complementary reactive side chain moieties.
A new type of multi-bit and energy-efficient magnetic memory based on current-driven, field-free, and highly controlled domain wall motion is disclosed. A meandering domain wall magnetic channel with precisely interspersed pinning regions provides the multi-bit capability. The magnetic free layer of the memory device has a perpendicular magnetic anisotropy and interfacial Dzyaloshinskii-Moriya interaction, so that spin-orbit torques induce efficient domain wall motion. Example pinning mechanisms of the domain wall corresponding to various magnetic memory cell designs are further disclosed, including a two-way switching mechanism and a four-way switching mechanism as examples. A synthetic antiferromagnetic stack is further designed to function as the free magnetic layer, giving rise to improvement in operation speed and reliability and reduction of the domain wall tilting.
G11C 11/155 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage électriques ou magnétiques particuliersÉléments d'emmagasinage correspondants utilisant des éléments magnétiques utilisant des éléments à pellicules minces avec une configuration cylindrique
G11C 11/02 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage électriques ou magnétiques particuliersÉléments d'emmagasinage correspondants utilisant des éléments magnétiques
G11C 11/16 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage électriques ou magnétiques particuliersÉléments d'emmagasinage correspondants utilisant des éléments magnétiques utilisant des éléments dans lesquels l'effet d'emmagasinage est basé sur l'effet de spin
76.
WEARABLE SENSOR SYSTEM FOR DETECTING AND MONITORING RESPIRATION
An example of a physiological monitoring system includes a sensor system configured to be worn by a subject. The sensor system can include a compliant substrate, a sensor array arranged on the compliant substrate, a sensor module, and an electronic control system communicatively coupled to the sensor system. The sensor system can be configured to obtain sensor data representing a physiology of the subject, and transmit the sensor data to the electronic control system. The sensor data can include one or more first audio signals generated by a plurality of microphones of the sensor array and one or more second audio signals generated by an ambient microphone of the sensor module. Further, the electronic control system can be configured to receive the sensor data from the sensor system and, pre-process the sensor data, which in turn can include generating a respiratory waveform based on the pre-processed sensor data.
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. (Allemagne)
Inventeur(s)
Lengyel, Ernst
Mann, Matthias
Curtis, Marion
Coscia, Fabian
Abrégé
The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
79.
COMPOSITIONS AND METHODS FOR REPLICON-MEDIATED GENE THERAPY
SindbisSindbis RNA replicons or Venezuelan equine encephalitis (VEE) replicons, can stabilize the longevity of the RNA replicon and can stabilize the expression of the cargo proteins encoded by the self-replicating RNA molecule or RNA replicon. Also disclosed herein are compositions and methods directed to the discovery that certain viral proteins, including viral proteins that repress internal cellular innate immunity, can stabilize the payload expression and replication of the replicons. Technologies provided herein provide stabilization mechanisms that can improve vaccines, gene therapies, and/or other gene delivery methods.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
The present disclosure relates to combination treatments for cancer. Specifically, the present disclosures relates to combination treatment of neuroendocrine tumors with an inhibitor of estrogen signaling or a retinoid, and radiation therapy or targeted radionuclide therapy.
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/502 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. cinnoline, phtalazine
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
Aspects of the present disclosure are directed to at least methods and compositions for diagnosis and/or treatment of diseases associated with aberrant levels of m5C RNA, including but not limited chromatin associate RNA (caRNA). The disease may comprise cancer and/or pre-cancerous cells. The disease may be associated with mutations in a TET2 pathway, including but not limited to mutations in TET2, IDH1, IDH2, and/or ASXL1 encoding genes. Treatment of a disease may comprises administration of one or more inhibitors of MBD6, TET2, and/or NSUN2. Also provided herein are methods of treatment of a disease in an individual comprising administering one or more inhibitors of MBD6, TET2, and/or NSUN2 to the individual determined to have aberrant m5C RNA modifications.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c.-à-d. autres que des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
Embodiments of the disclosure may comprise a photo-dependent proximity labeling system comprising an activatable probe and a retrievable substrate. The activatable probe may be, for example, an integrin binding peptide operatively coupled to a lumichrome molecule, and the retrievable substrate may be, for example, a biotin phenol. In some aspects, the activatable probe is activatable by light, thereby inducing labeling of adjacent molecules with a retrievable substrate. Also disclosed are methods for labeling proteins, identifying protein interactions or binding partners, and methods for identifying a therapeutic target in an individual using a composition of the disclosure.
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
83.
PREDICTING PROPERTIES OF BIOLOGICAL ENTITIES USING EVOLUTIONARY TREES
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for predicting a property of an input biological entity. The system generates an evolutionary feature representation of the input biological entity based at least in part on an evolutionary tree, and processes a model input that comprises the evolutionary feature representation sing a machine learning model to generate the prediction for the property of the input biological entity.
Systems and methods are provided herein for training a customized model. A method of constructing a customized generative model, comprising reading a plurality of synthetic images and associated latent representations; presenting each of the plurality of synthetic images to one or more users via a client computing platform; reading a plurality of inputs characterizing a plurality of values for a plurality of associated attributes of each of the plurality of synthetic images; based on the values of the associated attributes and the latent representations, training a regression model to predict the values of the attributes from the latent representations.
G06V 10/774 - Génération d'ensembles de motifs de formationTraitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source méthodes de Bootstrap, p. ex. "bagging” ou “boosting”
G06V 10/766 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la régression, p. ex. en projetant les caractéristiques sur des hyperplans
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 10/94 - Architectures logicielles ou matérielles spécialement adaptées à la compréhension d’images ou de vidéos
85.
METHOD FOR HIGHLY SENSITIVE DNA METHYLATION ANALYSIS
Methods, compositions and kits are provided to amplify an amount of genomic methylated DNA that can be subsequently analyzed and/or sequenced. It has particular use with small amounts of DNA, including, but not limited to cell free DNA samples. In some embodiments, the ratio of polymerase and methyltransferase is controlled in order to provide maximum yields. In some embodiments, a dual primase/polymerase is used.
In aspects, the present disclosure provides a method of treating or preventing premature ovarian insufficiency or polycystic ovary syndrome in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of (i) mesenchymal stem cells (MSCs) or secretome from MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); (ii) exosomes produced by MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); and/or (iii) exosomes comprising one or more effectors, wherein the one or more effectors comprises, consists essentially of, or consists of (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d), and wherein the amount of the effector per exosome is greater than the amount of the effector per exosome when produced by unmodified MSCs. In aspects, the present disclosure provides a method of preparing MSCs, exosomes, and secretome. In aspects, the present disclosure provides a method of preventing chemotherapy-induced damage in a male mammal.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
THE UNIVERSITY OF CHICAGO (USA)
Inventeur(s)
Simon, Jonathan
Schuster, David I.
Taneja, Lavanya
Abrégé
An optical resonator includes a plurality of mirrors positioned to reflect light along a closed path, thereby defining an optical axis. The optical resonator also includes one or more intracavity lenses positioned along the optical axis to establish a resonator mode whose waist that is located along the optical axis. The optical resonator also includes an intracavity nonlinear optical element that implements a nonlinear frequency-mixing process within the optical resonator. When input light is coupled into the optical resonator to excite the resonator mode, the intracavity nonlinear optical element nonlinearly converts at least some of the input light into nonlinearly generated light. This nonlinearly generated light may then be coupled out of the optical resonator, such as via transmission through one of the mirrors. In some embodiments, the waist is five microns or less. In some embodiments, the finesse of the optical resonator is 100 or less.
G02F 1/355 - Optique non linéaire caractérisée par les matériaux utilisés
G02F 1/37 - Optique non linéaire pour la génération de l'harmonique deux
G02F 1/39 - Optique non linéaire pour la génération ou l'amplification paramétrique de la lumière, des infrarouges ou des ultraviolets
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
88.
MICROFLUIDIC SYSTEM AND METHODS USING ACOUSTIC WAVES
The present document relates to systems and methods that implement acoustofluidics to manipulate particles within a microfluidic system. The method comprising delivering the sample through a first microchannel, wherein the sample comprises a first population of entities having a first characteristic and a second population of entities having a second characteristic that is different than the first characteristic; applying an acoustic wave through at least a portion of the first microchannel, thereby generating displacement of at least a portion of the first and second populations traveling through the first microchannel by way of acoustic radiation force and acoustic streaming; and separating the sample into a first separated population and a second separated population, wherein the first separated population comprises a majority of entities having the first characteristic and wherein the second separated population comprises a majority of entities having the second characteristic.
Radioisotope-labeled small molecule activity-based probes that target the cancer associated serine hydrolase neutral cholesterol ester hydrolase 1 (NCEH1) are described. The probes can undergo a reaction with the NCEH1, resulting in covalent bonding of a portion of the probe molecule to the NCEH1. Also described are methods of labeling NCEH1 in biological samples, such as cells or tissue, and methods of visualizing tumors using the radioisotope-labeled NCEH1 probes as tracer compounds, either alone or in combination with assessing the efficacy of a cancer treatment or potential cancer treatment.
C07C 271/48 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone de cycles aromatiques à six chaînons avec les atomes d'azote des groupes carbamate liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone de radicaux hydrocarbonés substitués par des atomes d'oxygène liés par des liaisons simples
90.
METHODS AND COMPOSITIONS FOR RAPID DETECTION AND ANALYSIS OF RNA AND DNA CYTOSINE METHYLATION
Aspects of the present disclosure are directed to methods, compositions, and kits for detection and analysis of DNA and RNA cytosine methylation. Certain aspects include methods, compositions and kits useful in bisulfite sequencing of methylated nucleic acids, including methylated nucleic acids from low-input samples such as cell-free DNA and cell-free RNA. Also disclosed are methods and compositions for detection and quantification of 5-hydroxymethylcytosine in DNA.
The disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein n, X1, and R'-R3 are defined herein: Also provided are pharmaceutical compositions comprising a compound disclosed herein, methods of inhibiting estrogen receptor alpha (ERa), methods of treating an estrogen- mediated disease in a subject requiring inhibition of estrogen receptor (ER) alpha (ERa), methods of treating one or more symptoms of menopause in a subject in need thereof, and methods of treating one or more side effects of hormone replacement therapy.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
A61K 31/4353 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques
To address the need in the art, the inventors have comprehensively characterized Aspects of the disclosure relate to novel antibody and antigen binding fragments. Further aspects relate to polypeptides comprising the antigen binding fragment(s) of the disclosure, and compositions comprising the polypeptides, antibodies, and/or antigen binding fragments of the disclosure. Also described are nucleic acids encoding an antibody or antigen binding fragment of the disclosure.
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
Provided herein are depolymerizable thermally activated delayed fluorescence polymers with exceptional light-emitting properties and programmable depolymerization under specific stressors.
Lithium-ion cells including fluoroether electrolytes and configured to promote lithium intercalation and (de)intercalation within graphite without fluoroether co-intercalation are provided. Processes for preparing the lithium-ion cells are further provided.
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFyEmploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p. ex. phosphates, silicates ou borates
H01M 10/0568 - Matériaux liquides caracterisés par les solutés
H01M 10/0569 - Matériaux liquides caracterisés par les solvants
Systems and methods for generating and manipulating a guided electromagnetic wave in a waveguide are provided. The optical system includes a waveguide, such as a two-dimensional waveguide, and an optical element disposed adjacent the surface of the waveguide. To generate the guided electromagnetic wave, a converging laser beam is generated and coupled to the waveguide by steering the converging laser beam towards an edge of the waveguide and with a beam center trajectory approximately parallel to a surface of the waveguide.
Lymphatic, nervous, and tumoral tissues, among others, exhibit physiology that emerges from three-dimensional interactions between genetically unique cells. A technology capable of volumetrically imaging genotypes and morphologies in a single de novo measurement would therefore provide a critical view into the biological complexity of living systems. The present disclosure achieves this by extending DNA microscopy, an imaging modality that encodes a spatio-genetic map of a specimen via a massive distributed network of DNA molecules inside it, to three dimensions and multiple length scales in developing zebrafish embryos.
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
The present disclosure concerns immunomodulatory compositions and methods of use for enhancing response to an antigen (e.g., in a vaccine), an immunotherapy (e.g., a cancer immunotherapy), or other immune stimulation. The disclosure describes immunomodulators having reduced toxicity and improved immune response compared with existing adjuvants. Further disclosed are methods for improving an immune response to a vaccine antigen, cancer immunotherapeutic, or other immune stimulating agent. The disclosure describes dimeric and polymeric immunomodulators comprising one or more pattern recognition receptor (PRR) agonist moieties and one or more NF-κB inhibitor moieties.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/21 - Retroviridae, p. ex. virus de l'anémie infectieuse équine
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
Aspects of the present disclosure are directed to methods and compositions for generation of antigen-specific regulatory T cells. Certain aspects relate to methods and compositions for generating tolerogenic antigen presenting cells, including tolerogenic dendritic cells. The present disclosure includes compositions, including nanocarrier compositions, comprising TLR agonists, and immunosuppressive agents and optionally an antigen. Also disclosed are methods for use of such compositions in generation of tolerogenic antigen presenting cells and treatment of certain conditions, including autoimmune and inflammatory conditions.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/366 - Lactones ayant des cycles à six chaînons, p. ex. delta-lactones
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
99.
POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION
Here, the inventors report that natural WT SARS-CoV-2 infection induces memory B cells expressing potently neutralizing antibodies against VOCs. Moreover, natural WT infection largely induced antibodies against spike epitopes outside of the RBD, most of which were non-neutralizing against WT and VOCs. Additionally. RBD-binding antibodies could be categorized into 3 distinct classes based on their binding profiles against RBD mutant constructs. The inventors identified VOC-neutralizing antibodies against three distinct regions of the spike protein, including the two epitopes on the RBD and one epitope in the NTD. Together, this study identifies that natural WT infection induces memory B cells that can produce neutralizing antibodies against recent SARS-CoV-2 VOCs and have the potential to be recalled by vaccination.
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 31/14 - Antiviraux pour le traitement des virus ARN
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
100.
SURVIVIN TARGETING POLYPEPTIDES FOR DETECTION AND TREATMENT OF CANCER
Aspects of the present disclosure are directed to survivin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such survivin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using survivin-targeting polypeptides.
